Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Skye Bioscience Inc (NASDAQ: SKYE) was $0.73 for the day, down -6.79% from the previous closing price of $0.78. In other words, the price has decreased by -$6.79 from its previous closing price. On the day, 0.88 million shares were traded. SKYE stock price reached its highest trading level at $0.76 during the session, while it also had its lowest trading level at $0.6975.
Ratios:
Our analysis of SKYE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.77 and its Current Ratio is at 4.77. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 06, 2025, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $2.
On August 15, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $10.Evercore ISI initiated its Outperform rating on August 15, 2025, with a $10 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 22 ’25 when Schwab Andrew J. sold 170,449 shares for $3.42 per share. The transaction valued at 582,936 led to the insider holds 57,493 shares of the business.
Schwab Andrew J. sold 60,956 shares of SKYE for $217,613 on Aug 21 ’25. The Director now owns 63,963 shares after completing the transaction at $3.57 per share. On Aug 22 ’25, another insider, 5AM Partners VII, LLC, who serves as the 10% Owner of the company, sold 170,449 shares for $3.42 each. As a result, the insider received 582,936 and left with 57,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SKYE now has a Market Capitalization of 23305774 and an Enterprise Value of -11684689.
Stock Price History:
The Beta on a monthly basis for SKYE is 2.65, which has changed by -0.7263158 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, SKYE has reached a high of $5.75, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is -42.39%, while the 200-Day Moving Average is calculated to be -70.10%.
Shares Statistics:
SKYE traded an average of 851.99K shares per day over the past three months and 646660 shares per day over the past ten days. A total of 30.99M shares are outstanding, with a floating share count of 19.88M. Insiders hold about 37.98% of the company’s shares, while institutions hold 25.59% stake in the company. Shares short for SKYE as of 1765756800 were 1076346 with a Short Ratio of 1.26, compared to 1763078400 on 1537748. Therefore, it implies a Short% of Shares Outstanding of 1076346 and a Short% of Float of 4.96.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Skye Bioscience Inc (SKYE) in the stock market.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.24 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.35 and -$1.41 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.16, with 7.0 analysts recommending between -$0.71 and -$1.66.
